U.S. Pregabalin Market at US$ 754M in 2024, Driven by Capsules (45%) & Neuropathic Pain (40%) Applications; Hospitals Lead End Users (50%) - Key Players Pfizer, Teva, Mylan (Nov 2025)

Leander, Texas and TOKYO, Japan - Nov. 26. 2025
United States Pregabalin Market reached US$ 754 Million in 2024 and is projected to reach US$ 1.21 Billion by 2033, growing at a CAGR of 5.2% during the forecast period 2025-2033.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/pregabalin-market?praveen

United States: Recent Industry Developments
✅ In November 2025, Pfizer Inc. (U.S.) launched an extended-release formulation of pregabalin for neuropathic pain management, offering improved patient adherence and reduced dosing frequency. The innovation enhances treatment convenience and effectiveness. This reinforces Pfizer's leadership in the U.S. neuropathic pain segment.

✅ In October 2025, Teva Pharmaceuticals USA expanded its pregabalin production facility in North Carolina with a $25 million investment to meet rising demand for generic formulations in the U.S. This strengthens Teva's manufacturing capacity and ensures consistent supply for healthcare providers.

✅ In September 2025, Mylan Pharmaceuticals (U.S.) introduced a new oral dispersible pregabalin tablet designed for patients with difficulty swallowing. The development addresses patient-centric treatment trends and boosts Mylan's competitiveness in the U.S. neuropathic pain market.

✅ In August 2025, Pfizer USA initiated a patient-support program offering financial assistance and medication counseling for pregabalin users, enhancing adherence and access. The program strengthens Pfizer's footprint in the U.S. specialty pharmaceuticals market.

Japan: Recent Industry Developments
✅ In November 2025, Pfizer Japan launched an extended-release pregabalin formulation targeting chronic neuropathic pain, offering improved dosing convenience and enhanced patient compliance. The product meets rising demand for innovative pain management therapies. This reinforces Pfizer Japan's leadership in the local neuropathic pain segment.

✅ In October 2025, Teva Japan expanded its production and distribution capacity for generic pregabalin to support growing demand in hospitals and pharmacies. The expansion ensures reliable supply and cost-effective options for Japanese patients.

✅ In September 2025, Mochida Pharmaceutical Co., Ltd. introduced a patient-friendly pregabalin capsule with improved bioavailability for diabetic neuropathy and fibromyalgia management. The innovation aligns with Japan's demand for optimized dosing and effective therapy.

✅ In August 2025, Eisai Co., Ltd. launched a patient education initiative focused on safe and effective pregabalin use, including adherence support and counseling for chronic pain management. The program reinforces Eisai's commitment to patient-centric healthcare solutions.

Pregabalin market Market: Key Drivers
- The Pregabalin market is expanding as the prevalence of neurological disorders, chronic pain, epilepsy, and anxiety-related conditions rises globally. Increasing awareness of effective treatment options and the growing geriatric population are driving demand across pharmaceutical and healthcare sectors.

- Technological advancements such as novel drug delivery systems, extended-release formulations, and bioequivalence improvements are enhancing efficacy, patient compliance, and safety. Growing adoption by healthcare providers, ongoing clinical research, and integration into combination therapies are accelerating market growth.

- Regulatory and healthcare factors such as approvals for new indications, patent expirations encouraging generic production, and healthcare policies supporting wider access to neurological medications are boosting demand. Rising healthcare infrastructure, increased insurance coverage, and focus on improving quality of life for chronic pain patients further strengthen market momentum.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pregabalin-market?praveen

Market: Major Key Players
Pfizer Inc., Mylan N.V., Teva Pharmaceuticals, Cipla Limited, and Medley Pharmaceuticals Limited, Torrent Pharmaceuticals Ltd, Lupin Limited, Zydus Cadila Healthcare Ltd, Sanofi, Genesis Biotec Inc, Chongqing Succeway Pharmaceutical Co., Ltd.'s, Xian tianguangyuan biotech co, Hebei yingong new material tech, Cangzhou Wanyou New Material Tech, Xi'an Kono chem co., Ltd.

Segment Covered in the Market:
By Product
Capsules lead with 45% share, driven by ease of administration, accurate dosing, and widespread prescription for neuropathic pain and epilepsy. Oral solutions account for 25%, preferred for pediatric and geriatric patients requiring flexible dosing. Tablets hold 20%, widely used for chronic pain and generalized anxiety disorders. Other forms, including injectables, represent 10%, primarily used in hospital settings for specialized treatment protocols.

By Application
Neuropathic pain dominates with 40% share, supported by growing prevalence of diabetic neuropathy, post-herpetic neuralgia, and chronic pain conditions. Epilepsy accounts for 28%, driven by increasing diagnosis rates and adoption of adjunct therapy. Generalized anxiety disorder (GAD) holds 18%, supported by rising mental health awareness and prescription trends. Other applications, including fibromyalgia and central nervous system disorders, capture 14%, addressing niche therapeutic needs.

By End User
Hospitals lead with 50% share, driven by inpatient treatment, chronic disease management, and specialist prescriptions. Retail pharmacies account for 30%, supporting outpatient access and chronic therapy adherence. Clinics hold 15%, used for pain management and psychiatric care. Other end users, including home healthcare and long-term care facilities, represent 5%, catering to patients requiring ongoing or specialized treatment.

Regional Analysis
North America - 27% Share
North America leads with 27%, driven by high prevalence of neuropathic pain, epilepsy, and growing geriatric population.

Europe - 26% Share
Europe holds 26%, supported by strong healthcare infrastructure and rising adoption of Pregabalin for pain management and anxiety disorders.

Asia Pacific - 35% Share
Asia Pacific dominates with 35%, fueled by increasing incidence of chronic pain, expanding pharmaceutical manufacturing, and rising healthcare access in China and India.

Latin America - 7% Share
Latin America accounts for 7%, driven by growing awareness and treatment of neuropathic pain and related disorders.

Middle East & Africa - 5% Share
Middle East & Africa hold 5%, supported by increasing healthcare expenditure and adoption of advanced pain management therapies.

Purchase this report before year-end and unlock an exclusive 30% discount:
https://www.datamintelligence.com/buy-now-page?report=pregabalin-market?praveen
(Purchase 2 or more Repots and get 50% Discount)

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.